Skip to content
Home/Companies/MedTech/EUROLyser
EU

EUROLyser

MedTech·Austria·Exited 2022·Held 3yr

EUROLyser is a diagnostics, animal & environmental health company, headquartered in Austria.

Entry
2019
Hold
3yr
Exit
2022
Est. EV
–

Who owns EUROLyser?

EUROLyser was owned by ARCHIMED through MED Platform I (2019 vintage) from 2019 to 2022, exited via Trade Sale.

Buyer identity and MOIC available on Pro.

Hand-verified · updated 2026-04-21

ARCHIMED
Investor
ARCHIMED
MED Platform I · 2019 · Buyout

Key facts

HQAustria
SectorDiagnostics, Animal & Environmental Health
Exit Type
Trade Sale
Buyer
MOIC
Exit Year
2022

More from MED Platform I

Other portfolio companies in the same fund.

CARSO
Active
MedTechFrance· 2021
Ad-Tech Medical Instrument
Exited 2024
MedTechUS· 2020
to
Ametris (ActiGraph)
Exited 2026
HealthTechUS· 2020
to
NAMSA
Active
MedTechUS· 2020
ZYTOMICS
Active
MedTechGermany· 2020
Bomi Group
Exited 2023
MedTechItaly· 2019
to

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Aflo
Active
Clarendon Fund ManagersUnited Kingdom
Lattice Medical
Active
Finovam GestionFrance
QTAS
Active
OVNI CapitalGermany
Axomove
Active
Go CapitalFrance· 2026
Bioliberty
Active
Scottish National Investment BankUK· 2026
CertHub
Active
Cusp Capital PartnersGermany· 2026
Data refreshed weekly · Sourced from public filings